17 Million for
Future Cancer Diagnoses

inveox Acquires Further Investment


05.08.2019 Munich, Germany 

After a successful market entry in the DACH Region (Germany, Austria and Switzerland) and the opening of a subsidiary office in Krakow, Poland, inveox continues to grow. With its largest investment so far of 17 million euros, the Munich startup will begin the series-level production of their AI-supported automation system in order to make cancer diagnoses faster and more reliable. 

It all began with an idea: to help people by significantly improving the reliability of cancer diagnoses. To the founders, concepts like digitalization, automation and artificial intelligence also belong in the world of histopathology. These have the potential to enable faster and safer cancer diagnoses by enhancing the arrival and processing of tissue samples in a lab. Four business angels believed in this vision, and in 2017 they supported the founders with an investment of
1 million euro
s. In the summer of 2018 there was a growth investment of
5 million from the same investors.
To Managing Partner Dominik Sievert, the most recent investment means more than financial support: the investors believe in us because inveox has displayed unprecedented strong growth in just a short time. They believe in our product, our leadership and our vision, and more importantly they provide us with an invaluable asset beyond the investment: mentoring. 

“My founding partner Dominik Sievert and I are very grateful that our investors put such great trust in us and our vision. Together we are working towards the goal of using our innovation capacities to develop technologies that can be put to serve people. We want to help lab technicians who give their best every day at labs and we want to ensure the safety of patients as well as the speed and reliability of the entire diagnostic process. That’s why we will use this further investment for our forthcoming series production and expansion into new markets,” says Managing Partner Maria Sievert. 

Currently, the IoT/SaaS integral system – consisting of a lab automation machine, an intelligent sample container, and AI-enhanced software – is being implemented with several customers in the D/A/CH region including well-known university clinics in Germany. The entry into further markets within and outside of Europe is planned for the later this year. 

About inveox GmbH:  

inveox  GmbH, founded in 2017 in Munich,  develops systems to digitize, automate and connect pathology laboratories. The goal is to increase the safety and reliability of cancer diagnoses while simultaneously improving the efficiency and profitability of labs as well as unlocking the potential for personalized diagnostics driven by big data and artificial intelligence. 

Since its founding,  inveox  has won numerous awards and been part of several accelerators of renowned companies,  such as “Digital Health”  (Roche Diagnostics / Plug&Play) and the upcoming Texas Medical Center Accelerator 2019 in Houston, Texas. inveox  was voted “Start-up of the Year” by  Für-Gründer magazine in the year of its founding and made it on the Forbes list of the “100 most promising  startups  2018”.    At the end of 2018,  inveox  opened a subsidiary in Poland (Krakow) and in 2019 became a member of the World Economic Forum. 


Press contact:   

Tina Holtz | Head of Marketing & Communications
tina.holtz@inveox.com | +49 157 92348482
Lichtenbergstr. 8
85748 Garching / Munich

published on 31st July 2019